Experienced in Neuroendocrine Carcinoma of the Cervix

Dr. Tyler C. Gunter

Radiation Oncology
Ou Health Partners Inc
800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Neuroendocrine Carcinoma of the Cervix
Ou Health Partners Inc
800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tyler Gunter is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Gunter is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. His top areas of expertise are Prostate Cancer, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Ependymoma. Dr. Gunter is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Hospital Affiliations
O U Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

OU HEALTH PARTNERS INC
800 Ne 10th St, Ouhp Stephenson Cancer C, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Recruiting
Publish Date: January 22, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: June 06, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
View 5 Less Clinical Trials

6 Total Publications

Mask-based vs. frame-based stereotactic radiosurgery: A systematic review.
Mask-based vs. frame-based stereotactic radiosurgery: A systematic review.
Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Published: January 05, 2025
Similar Doctors
Distinguished in Neuroendocrine Carcinoma of the Cervix
Dr. John S. Thompson
Radiation Oncology
Distinguished in Neuroendocrine Carcinoma of the Cervix
Dr. John S. Thompson
Radiation Oncology

Ou Health Partners Inc

900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4311
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Thompson is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Thompson is rated as an Advanced provider by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, and Vulvar Cancer. Dr. Thompson is currently accepting new patients.

Advanced in Neuroendocrine Carcinoma of the Cervix
Dr. Nathan W. Uy
Radiation Oncology
Advanced in Neuroendocrine Carcinoma of the Cervix
Dr. Nathan W. Uy
Radiation Oncology

Stillwater Medical Center Authority

600 S Adams St, The Cancer Center East, 
Stillwater, OK 
 (50.1 miles away)
405-372-1775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nathan Uy is a Radiation Oncologist in Stillwater, Oklahoma. Dr. Uy is rated as an Advanced provider by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Prostate Cancer, and Metastatic Pleural Tumor. Dr. Uy is currently accepting new patients.

Experienced in Neuroendocrine Carcinoma of the Cervix
Dr. Andrea L. Johnston
Radiation Oncology
Experienced in Neuroendocrine Carcinoma of the Cervix
Dr. Andrea L. Johnston
Radiation Oncology

Ou Health Partners Inc

800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4088
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrea Johnston is a Radiation Oncologist in Oklahoma City, Oklahoma. Dr. Johnston has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. Her top areas of expertise are Pancreatic Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, and Cervical Cancer. Dr. Johnston is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunter's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile